202 related articles for article (PubMed ID: 31849109)
1. Distribution of diffuse plexiform neurofibroma on the body surface in patients with neurofibromatosis 1.
Ehara Y; Koga M; Imafuku S; Yamamoto O; Yoshida Y
J Dermatol; 2020 Feb; 47(2):190-192. PubMed ID: 31849109
[TBL] [Abstract][Full Text] [Related]
2. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
4. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
[TBL] [Abstract][Full Text] [Related]
5. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1.
Darrigo Junior LG; Ferraz VEF; Cormedi MCV; Araujo LHH; Magalhães MPS; Carneiro RC; Sales LHN; Suchmacher M; Cunha KS; Filho AB; Azulay DR; Geller M
Brain Behav; 2022 Jun; 12(6):e2599. PubMed ID: 35506373
[TBL] [Abstract][Full Text] [Related]
7. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1.
Ehara Y; Yamamoto O; Kosaki K; Yoshida Y
J Dermatol; 2018 Jan; 45(1):53-57. PubMed ID: 28891076
[TBL] [Abstract][Full Text] [Related]
8. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.
Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC
Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344
[TBL] [Abstract][Full Text] [Related]
9. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
10. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
11. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
12. Giant plexiform neurofibroma in a patient with neurofibromatosis type I.
Rallis E; Ragiadakou D
Dermatol Online J; 2009 May; 15(5):7. PubMed ID: 19624985
[TBL] [Abstract][Full Text] [Related]
13. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
[TBL] [Abstract][Full Text] [Related]
14. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
15. [Progress in diagnosis and treatment of neurofibromatosis in children].
Wang S; Li Y; Zhang J; Ni X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jun; 36(6):477-482. PubMed ID: 35822370
[No Abstract] [Full Text] [Related]
16. [Unilateral facial and cerebral hyperplasia associated with neurofibromatosis type 1. Report of four patients].
Pascual-Castroviejo I; Pascual-Pascual SI; Burgueno M; Martin-Perez M; Palencia R; Garcia-Segura JM; Valero C
Rev Neurol; 2006 Sep 16-30; 43(6):346-52. PubMed ID: 16981165
[TBL] [Abstract][Full Text] [Related]
17. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
19. Fatal acute retropharyngeal hemorrhage in neurofibromatosis type 1.
Peyron PA; Pollanen MS
Forensic Sci Med Pathol; 2017 Dec; 13(4):436-440. PubMed ID: 29080953
[TBL] [Abstract][Full Text] [Related]
20. Plexiform neurofibroma of the eye region occurring in patients without neurofibromatosis type 1.
Bechtold D; Hove HD; Prause JU; Heegaard S; Toft PB
Ophthalmic Plast Reconstr Surg; 2012; 28(6):413-5. PubMed ID: 22836801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
